Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm…
In an observational comparative effectiveness study of targeted vs non-targeted therapy for metastatic renal cell carcinoma (mRCC), older patients saw modest survival advantages when treated with targeted therapies.…
Antoine Azar, MD, clinical director of the Division of Allergy and Immunology at Johns Hopkins Bayview Medical Center, discusses a patient’s journey to diagnosis and treatment of adult…
In this video, Dr. Daniel George, MD, discusses the results of a sunitinib study that helped change the treatment landscape for renal cell carcinoma (RCC). Compared to placebo,…
An interim analysis of the CHECKMATE920 phase IIIb/IV clinical trial found that renal cell carcinoma (RCC) patients with brain metastasis show encouraging anti-tumor activity in response to nivolumab…
Results from the CARMENA trial, presented at the 2019 annual meeting of the American Society of Clinical Oncology suggest that cytoreductive nephrectomy should no longer be considered the…
Findings from a planned sub-analysis of clinical trial data comparing treatment options for renal cell carcinoma patients (RCC) with sacromatoid history were presented at the 2019 American Society…
This video depicts an MRI of an entire human brain, donated by a 58-year-old female who died as a result of non-neurological causes, at 100 micron resolution. The…
A pilot study showing improved outcomes for metastatic renal cell carcinoma (mRCC) patients who were treated with immune checkpoint therapy after surgery, as compared with just immune checkpoint…
Recurrence after metastasectomy is common for patients with metastatic renal cell carcinoma (mRCC). In this study, treating with pazopanib after metastasectomy was shown to offer no additional survival…
